MeSH term
Frequency | Condition_Probility | Female | 17 | 0.0 |
Gene Dosage | 3 | 0.0 |
Humans | 35 | 0.0 |
Male | 10 | 0.0 |
Nucleic Acid Hybridization | 7 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 25 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Apoptosis | 3 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Down-Regulation | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Protein Subunits | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Chromosome Mapping | 8 | 0.0 |
In Situ Hybridization, Fluorescence | 10 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Oncogenes/*genetics | 4 | 5.0 |
Up-Regulation | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics/metabolism | 2 | 7.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
Esophageal Neoplasms/*genetics/metabolism | 2 | 14.0 |
*Gene Amplification | 6 | 1.0 |
Mutation | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase/genetics/*metabolism | 2 | 13.0 |
Aged | 5 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Comparative Study | 7 | 0.0 |
Disease Progression | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Middle Aged | 5 | 0.0 |
Prognosis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase/*genetics | 2 | 22.0 |
Catalytic Domain | 2 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
Chromosomes, Human, Pair 3/*genetics | 4 | 1.0 |
Neoplasm Staging | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
*Oncogenes | 3 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Chromones/pharmacology | 3 | 1.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Gene Amplification | 3 | 0.0 |
Morpholines/pharmacology | 3 | 1.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Animals | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*genetics/metabolism | 3 | 100.0 |
Brain Neoplasms/*enzymology/genetics | 2 | 66.0 |
Genetic Screening/methods | 2 | 1.0 |
Glioblastoma/*enzymology/genetics | 2 | 100.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Phosphoric Monoester Hydrolases/genetics/metabolism | 2 | 9.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Tumor Suppressor Proteins/genetics/metabolism | 2 | 6.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Base Sequence | 3 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Adult | 4 | 0.0 |
Child | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
English Abstract | 2 | 0.0 |
Metaphase | 2 | 1.0 |
Head and Neck Neoplasms/*genetics | 2 | 2.0 |
Carcinoma, Squamous Cell/enzymology/*genetics/pathology | 2 | 40.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
